Novartis unveils promising interim Phase 2 data for iptacopan in C3G
In the Phase 2 study, iptacopan reduced 49% proteinuria, improved plasma C3 levels, stabilised renal function, and was…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Oct 20
In the Phase 2 study, iptacopan reduced 49% proteinuria, improved plasma C3 levels, stabilised renal function, and was…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Oct 20
Finerenone is an investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, which prevents kidney and cardiovascular damage
26 Oct 20
Jardiance reduced risk of cardiovascular death and hospitalisation for heart failure, along with serious adverse kidney outcomes in…
23 Oct 20
Roche and Atea partner will jointly develop AT-527 an orally administered direct-acting antiviral (DAA) currently being studied under…
23 Oct 20
Veklury becomes the first and only FDA approved treatment for Covid-19 in the US, which helps recovery of…
22 Oct 20
Branaplam is an orally administered small molecule RNA splicing modulator, currently being studied for the treatment of spinal…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Oct 20
The FDA has granted the Prescription Drug User Fee Act (PDUFA) date to announce its regulatory decision, during…
20 Oct 20
Phase 3 CheckMate-9ER trial showed that Opdivo plus Cabometyx improved overall survival, progression-free survival and objective response rate
19 Oct 20
The US regulator approved Genentech’s Supplemental New Drug Applications for Venclexta plus azacitidine under its RTOR and Project…
16 Oct 20
The acquisition would add Disarm's axonal degeneration therapies to expand Lilly's pain and neurodegeneration capabilities
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates